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6 Rs of Radiobiology
A B S T R A C T
Radiations in medicine cover a wide range of applications, predominantly in diagnostic imaging and radio-
therapy, encompassing photons (x- and γ-rays) and particle radiation, as well as with the use of liquid sources in
nuclear medicine focusing on physiological functional imaging, tumour detection or targeted radiotherapy. The
biological interactions of ionizing radiation leads naturally to questions of benefits and risk following dose
exposures. The inherent properties of ionizing radiation in sterilising dividing cells can offer immense benefits
with respect to tumour control, but radiation can also deliver potential harm in the form of normal tissue toxicity
or carcinogenesis. The advances in radiation technology, offering accurate and reliable dose delivery, in concert
with greater understanding of the underpinning radiobiological effects are creating an ever-growing ability to
extract maximum benefit and minimise risk. The radiobiological effects fall broadly under the headings of
mutagenesis, chromosomal aberrations, radiation induced genomic instability and cell death. The enormity of
evidence derived from these underlie the mechanism of the six Rs of controlled radiotherapy: repair, re-
population, reoxygenation, redistribution, radiosensitivity and most recently, remote bystander cellular effects
(including low dose hyper-radiosensitivity, adaptive response, hormesis, abscopal effect and immune response).
Herein, we seek to discuss how such understanding leads to optimised radiotherapy.
1. Introduction
In the broadest of terms, medical radiations are accessed for diag-
nosis and radiotherapy, with the use of photons (x- and γ-rays) and
particle radiation (proton and carbon) well-embedded in routine med-
ical centre practices. Ionizing radiation interactions within the human
body arise from external sources, also from radioactive isotopes in-
troduced internally, offering great benefits in specific medical circum-
stances, but with the capacity to cause harm if used inappropriately or
incorrectly. Understanding of the science-base is essential for optimi-
sation purposes.
Ionizing radiation deposits energy in highly structured tracks of
ionization and excitation events, with the general structure of these
tracks varying for the different types of radiation, resulting in differ-
ences in biologically effectiveness for a given dose (Hill, 2019). Linear
energy transfer (LET) is often used to describe the average rate of en-
ergy loss along the track of an ionizing particle. Accordingly, different
forms of radiation can be classified as either sparsely ionizing low LET
radiations (such as photons and electrons) or more densely ionizing
high LET (such as alpha-particles and carbon ions), although there is
inevitably a spectrum of LET values.
Radiotherapy relies on molecular damage produced by ionizing
radiation, which can occur either through direct interaction or in-
directly as a result of interaction with the surrounding water (Hall and
Giaccia, 2012). Directly ionizing radiation has sufficient kinetic energy
to disrupt particular atomic structures within DNA in the tissue through
which they pass, producing chemical and biological changes. Ionizing
radiation has the ability to remove tightly bound electrons from their
atomic orbits, causing the atom to become charged, more commonly
termed ionized. This ionized atom can then react with neighbouring
atoms and ions forming new chemical bonds. In tissue, the energy re-
leased by an ionizing event is typically of the order of 34 eV in creating
an ion pair, sufficient to break strong chemical bonds, such as the C]C
bond with an associated energy of 4.9 eV (Hall and Giaccia, 2012). The
charged atom will further interact with several atoms or molecules.
Ionization events in the surrounding of water can result in the release of
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highly reactive free radicals, most notably hydroxyl radicals which are
able to diffuse and react with DNA.
Radiotherapy and radiosurgery are important in the medical man-
agement of a large range of conditions that manifest in dysfunction
resulting from changes in tissue and tissue response (structure, orga-
nisation, cellular division etc.), cancer in particular. The basis of ra-
diation therapy is to deposit sufficient energy via atomic ionizations to
eliminate the tumour cells, while sparing as much as possible the
normal tissues or organs that surround a tumour. Ideally, the greater
the absorbed energy (or radiation dose) to the tumour tissue, the
greater the probability of lethality to the tumour. Hence, the technical
ability to localise and maximise energy deposition within a well-defined
volume (the tumour and its normal tissue margin) is of paramount
importance in the delivery of radiotherapy. The efficacy of radiation
therapy is further improved by recent technological and biological
advancements and developments. The advances in technology include
improved physical delivery of beams and imaging, with better-quality
dose distribution, for instance from use of intensity modulated and
image guided radiotherapy (IMRT and IGRT), stereotactic radiosurgery,
stereotactic body radiotherapy (SRBT) and many others - resulting in
maximised dose to the tumour and minimised dose to surrounding
normal tissues. These advances in radiotherapy planning and delivery,
with accurate targeting of radiation to the tumour have facilitated
greater conformity, reduced planning margins and the delivery of an
increased dose to the tumour, potentially resulting in improved patient
outcomes.
These advances taking place in radiation technology, not least ac-
curate dose delivery via precise measures of control, in concert with
greater understanding of the underpinning radiobiological effects are
creating an ever-growing ability to extract maximum benefit while
minimising the risk of harm.
The radiobiological effects of ionizing radiations fall broadly under
the headings of cell death, mutagenesis, chromosomal aberrations, ra-
diation induced genomic instability. The enormity of evidence derived
from these underlie the so-called six Rs of controlled radiotherapy:
repair, repopulation, reoxygenation, redistribution, radiosensitivity and
most recently, remote bystander cellular effects (including low dose
hypersensitivity, adaptive response, hormesis, abscopal effects and
immune response). How such understanding can lead to optimised
radiotherapy is described below.
2. Radiobiology
2.1. Effects of radiation in cells – Damage, repair and cell death
The impact of radiation on living human cells/tissues varies with
the radiation modality and the differing types and properties of tissues.
Moreover, ionizing radiation generates chemical, biological, biochem-
ical and physiological changes, succinctly described by JB Little (1968)
as shown in Fig. 1 (Little, 1968). Chemically, each deposition of 34 eV is
sufficient to produce an ion pair and this can trigger a cascade of me-
chanisms that can contribute to cell death with increasing dose. Bio-
logically, ionizing radiation induces several basic types of response
from the cells such as oxidative stress, activating and inactivating of
different signalling pathways, and damage to deoxyribonucleic acid
(DNA); the latter include base loss, base modification, dimer, single-
and double-strand breaks (Hill, 2019). Double strands break (DSB) are
considered the most lethal form of DNA damage. A percentage of these
DSBs will have additional strand-breaks and/or based damage within a
few base pairs, and are referred to as complex DSBs, which are much
more difficult to repair than simple DSB. While typically these DSBs will
be quickly repaired by the cell, miss-repair can result in mutations, and
alternatively broken ends may undergo illegitimate re-joining with
other nearby DSB resulting in chromosomal aberrations, which may or
may not be lethal. If the cell survives, there is a risk of future cancer
development. Besides the DSBs, radiation does directly damage the
atomic structures of proteins and lipids (Pouget et al., 2018) and in-
terferes with membrane function, although these may be temporary
changes since a viable cell is capable of replacing damaged macro-
molecules. Such radiation effects do activate a series of downstream
signalling effects that may even persist for an extended period of time
following irradiation; this can result in a variety of responses including
cell death. Cell death can be triggered by apoptosis, necrosis, mitotic
catastrophe, autophagy and all these events could occur concurrently
and are dependent on the cell type. Cells that undergo apoptosis are
typically significantly more radiosensitive then cells which pre-
dominantly die as a result of mitotic catastrophe (Hall and Giaccia,
2012). Tumour cell death is beneficial but cellular and vascular tissue
damage in the surrounding normal tissue or organs can be detrimental.
Mammalian cells also have the ability to repair radiation damage by
means of complex enzymatic systems. Both normal and tumour cells
have the ability to repair radiation induced damage. Due to gene mu-
tation, some tumour cells appear to repair faster than normal cells,
probably due to functional loss of repair systems which have longer
half-times of repair, and also may repair with reduced fidelity.
The three different type of induced radiation damage are: (i) lethal
damage which are irreversible and irreparable and that lead to cell
death (Hall and Kraljevic, 1976; Hall and Giaccia, 2012); (ii) sublethal
damage (Elkind and Sutton, 1959); and (iii) potentially lethal damage
(PLD) (Phillips and Tolmach, 1966). These three types of damage are
related to DNA single and DSBs which are the basic lesions responsible
for further chromosomal injury and radiation-induced cell inactivation.
In human cells, radiation induced DNA DSBs spontaneously trigger a
DNA damage response (DDR) process. The DDR process comprises of a
complex network of proteins that initiate and coordinate DNA damage
signalling and repair activities. DNA repair depends on several factors,
such as types of damage, cell cycle phase of cell (kinases and cell cycle
check points) and repair pathways. For single-strand break (SSB), the
three modes of excision repair are Base Excision Repair, Nucleotide
Excision Repair and Mismatch Repair. The two major pathways of re-
pair for DSBs are Homologous Recombination (HR) repair and Non-
Homologous End-Joining (NHEJ) repair. The HR repair requires an
undamaged DNA strand as a template to repair without error the da-
maged cells and occurs primarily in the S/G2 phase. Conversely, NHEJ
occurs mainly during G1 phase of the cell cycle, and does not require a
template and they are error prone in repair. Incorrect DNA repair can
result in genetic aberrations or tumour cell death. Tumour cells that
also have the capacity to repair damage induced by radiation are often
radio-resistant as they typically occupy a more hypoxic environment.
Radiation induced damage can be detected/measured using a range
of methodologies, for example an early cellular response to DSBs could
be detected with the formation of γH2AX of the damaged DSBs in the
nucleus (Redon et al., 2009; Mah et al., 2010; Hill, 2019) and can be
used to evaluate underlying repair mechanisms (not discussed herein)
and associated kinetics (Figueroa-González and Pérez-Plasencia, 2017).
Common methods used to measure chromosomes aberration and mu-
tation are the micronuclei assay; cytokinesis-block micronucleus; cy-
tokinesis-block micronucleus cytome (CBMN) Cyt assay and many
others (not discussed here). The micronuclei assay measures the chro-
mosomal loss or breakage by the expression of micronuclei (MN) after
cells have completed one nuclear division with the aid of cytochalasin B
that inhibits cytoplasmic division enabling the accumulations of all
dividing cells at the bi-nucleated stage. CBMN assay effectively measure
the genotoxic, cytostatic and cytotoxic effects of radiation on the cells
(Fenech, 2007). Moreover, it provides the proliferative index of the
treated cells and their radiosensitivity (Guo et al., 1999). The viability
status (apoptosis and necrosis) is shown in Fig. 2; the mitotic status
(mono-nucleated, bi-nucleated cells, giant nucleated cell and multi-
nucleated cells) in Fig. 3; and its chromosomal damage or instability
status (presence of MN, nucleoplasmic bridges (NPBs), nuclear buds
(NBs)), appropriate for radio-sensitivity measurements (Fenech et al.,
1999), is shown in Fig. 4.
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Briefly, MNs are induced chromosome aberration due to unrepaired
or misrepair DSBs by the NHEJ repair pathway (mentioned above).
NPBs are biomarkers of DNA misrepair and/or telomere end-fusion.
NPBs originate from dicentric chromosomes (induced by misrepair of a
chromosome break). Assessment of NPB is a form of measurement of
asymmetrical chromosome rearrangement (dicentric and ring chromo-
some) in cells after a single division (Thomas et al., 2003). NBs are
biomarkers of the elimination of over-amplified DNA and/or DNA re-
pair complexes. This cellular process is characterized by the production
of multiple copies of a particular gene or genes to amplify the
Fig. 1. Effects of radiation in cells (adapted from Little, 1968).
Fig. 2. Viability status: (A) two necrotic cells and (B) an apoptotic cell (x1000 magnification).
M.T. Chew, et al. Radiation Physics and Chemistry 178 (2021) 108994
3
phenotype and NBs are formed because of the capacity of the nucleus to
‘sense’ excess DNA that does not fit well within the nuclear matrix
(nuclear housekeeping) (Fenech and Crott, 2002).
2.2. Linear quadratic model for fractionated radiotherapy
The Linear Quadratic (LQ) model for cell kill is commonly used in
radiotherapy for quantitative predictions dose/fractionation de-
pendencies (Jones and Dale, 2018). There are two important para-
meters to cell kill in the LQ formalism, embodied in the equation:
E = αd + βd2 2.1
Where:
E (logarithmic cell kills) is the fraction of cells killed by an absorbed
dose d;
α is the linear component of cell kills related to DSBs caused by a
single hit of radiation;
β describes double hits (the quadratic) component of cell kills.
The α/β ratio is the dose, typically quoted in gray (Gy), when the
number of cells killed by a single hit is equal to the cells killed by the
quadratic components. The higher the α/β ratio, the greater the
number of cells killed. Early responding tissues (jejunum) have a high
α/β ratio and late responding tissues (spinal cord, brain) have a low α/
β ratio (see Table 1). The α/β ratios describe the effectiveness of the
dose, often used to quantify fractionation sensitivity of tissues.
3. Beneficial and detrimental effects (a two-edged sword)
Sparsely ionizing radiations are limited by the 5 ‘Rs’ of radiobiology
(Steel et al., 1989), more recently the 6 ‘Rs’, as previously mentioned.
The goal of radiation is to kill all tumour cells without triggering serious
damage to the normal surrounding tissues and organs at risk (OAR). To
achieve this goal, fractionated radiotherapy was implemented to spare
late-reacting normal tissues which have a higher repair capacity; the
use of single high dose treatment was considered inefficient for other
reasons (lack of elimination of hypoxic cells and exposure of cells
within resistant phases of the cell cycle) and could be detrimental not
only to the tumour but also to surrounding normal tissues if included in
the high dose treatment volume. Fractionation, in contrast, allows tu-
mour cells to redistribute into the mitotic phase which is radio-sensitive
and it reduces hypoxia by reoxygenation (Withers, 1975).
3.1. The 5 ‘Rs’
3.1.1. Repair
In mammalian cells, radiation induced DNA DSBs spontaneously
trigger a DDR process as described above and DNA repair depends on
several factors, such as types of damage, cell cycle phase of cell and
repair pathways. The S and G2 phases are significant for HR while,
NHEJ occurs primarily during G1 and early S phases of the cell cycle.
The repair phase of damaged DNA for both tumour cells and normal
cells if repaired incorrectly would contribute to chromosomal aberra-
tions/mutation or tumour cell death. Tumour and normal tissue cells
Fig. 3. Mitotic status: (A) mononuclear cells; (B) single binucleated cell; (C) multinucleated cell joined together; (D) one single giant nucleated cell (x1000 mag-
nification).
Fig. 4. Instability status: (A) nucleoplasmic bridge; (B) nuclear bud; (C) micronuclei in a binucleated cell (x 1000 magnification).
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that have a high capacity to repair DNA damage induced by radiation
are said to be radio-resistant.
Potential lethal damage plays an indirect role in affecting the
radiosensitivity of cells and the radiocurability of tumours when the
PLD cells are allowed to repair by arresting their proliferation
(Weichselbaum et al., 1982; Weichselbaum, 1986; Weichselbaum and
Beckett, 1987).
The above processes, including the repair kinetics of cells, with fast
and slow repair half-time components, can be formulated mathemati-
cally and are useful in clinical decision making for optimisation pur-
poses (Dale, 2019; Jones and Hopewell, 2018).
3.1.2. Reassortment/redistribution
Redistribution refers to radiation-induced cell cycle effects (Withers,
1975). The Cell Cycle is a 4-phases process comprising of Gap 1 (G1),
Synthesis (S), Gap 2 (G2), Mitosis and G0 (dormant phase). After com-
pletion of the cycle, the cell will either start the whole process again
from G1 or exit the cycle through G0. The phases in the cell cycle be-
tween mitosis and the next is known as Interphase (G1, S and G2) as
shown in Fig. 5.
To maintain genomic integrity, there is a complex network of cyclin-
dependent kinases (CDKs) and checkpoints which prevent or delay
progression of cells through the cell cycle. Both, G1-S and G2-M phases
transition are under constant surveillance for protection of cells from
exogenous and endogenous DNA damaging agents. Ionizing irradiation
induces arrest in the G1, S and G2 phases of the cell cycle.
The G1 checkpoint is vital in initiation of cell division and is sen-
sitive to growth factors, nutrient and other conditions to promote
proliferation. Once initiated, the cell increases in size and duplicate the
cellular contents. Cells that are irradiated during this phase will exhibit
a delay in entering into S phase. Cells irradiated at S phase demonstrate
a dose-dependent reduction in the rate of DNA synthesis and this in-
creases the overall length of time to replicate their DNA substances
(Joiner and Van der Kogel, 2016). S-phase cells have the opportunity to
arrest and repair in the G2 phase. The DDR process is triggered to repair
radiation induced DNA DSBs, a complex association between check-
point activation and DNA repair with the involvement of proteins and
related genes. There are two radiation-inducible checkpoints at G2
phase, the first checkpoint being a dose-dependent block progression of
radiation damaged G2 cells to G1-or S- phase (Sinclair, 1968). Post ra-
diation, the second G2 checkpoint is activated and prevent radiation-
damaged G2-phase cells from progressing through G2 and prematurely
enter mitosis with unrepaired radiation-induced DNA damage (Xu









































































































































































































































































































































































































































































































































































































































































































































































































Fig. 5. Cell cycle phases with the most and least radiosensitive phases.
M.T. Chew, et al. Radiation Physics and Chemistry 178 (2021) 108994
5
(Prophase, Metaphase, Anaphase and Telophase) before cytokinesis.
Cytokinesis involves a division of the cytoplasm, being the process
where the parent cells becomes two identical daughter cells.
Cells have different radiation sensitivities at different phases of the
cell cycle; the most radiation sensitive phase is late G2/M phase, fol-
lowed by G2, G1, early S, while the most radio-resistant is late S phase
(Tobias, 1985) as shown in Fig. 5.
Tumour cells are more sensitive in G2/M phases of the cell-cycle
than G1/S and, when they are blocked in G2/M due to a functional G2
checkpoint after exposure to radiation, they are more susceptible to the
subsequent radiation (Ng et al., 2013). Moreover, tumour cells have
shorter cell cycle times in comparison to normal tissues. In contrast,
normal cells are mostly in G0/G1 due to G1 checkpoint and are thus less
susceptible to this type of sensitisation (Ng et al., 2013). Fractionation
in radiotherapy enables the surviving cells from one fraction, which will
be predominantly in the radioresistant phases, to redistribute them-
selves into a more sensitive phase of the cell cycle to allow effective
killing (therapeutic gain) for the subsequent fraction. This also favours
survival of normal late responding tissues (Withers, 1975; Hall and
Giaccia, 2012).
3.1.3. Repopulation
Repopulation also known as Regeneration where fractionation
radiotherapy allows normal tissues to repopulate which is important to
reduce overkill and severe side-effects for radio-sensitive tissues such as
the skin or mucosa and surrounding normal tissues. For the early re-
sponding normal tissues, the fractionation interval brings about in-
crease in radiation tolerance with increasing overall treatment time.
When the interval time between two dose fraction exceeds the cell
cycle, there will be an increase in the number of cells surviving due to
cell proliferation. Just as normal cells can proliferate, tumour cells can
also respond with an increase in rate of repopulation. At the same time
as the tumour shrinks post treatment, surviving tumour cells proliferate
at an accelerated rate since tumour cells have an uncontrolled growth
rate, and this counteracts the cell killing effects of radiotherapy. The
repopulation time of tumour cells varies during radiotherapy (Withers,
1975) and has a negative effect on radiation doses. Consequently, it
follows that restriction of overall treatment time can be advantageous
in rapidly proliferating tumour types provided that normal tissue
fractionation is sufficient. An optimisation of the two processes can in
principle be achieved by graphical or differential calculus methods
providing that the cell and tissue parameters used are sufficiently well
known (Jones and Dale, 2000).
3.1.4. Reoxygenation
The role of oxygen on biological response by affecting the chemical
changes produced directly in the cells by radiation was first demon-
strated by Gray et al. (1953). Cells irradiated under hypoxic conditions
are significantly less sensitive to radiation than when oxygen is present.
Following irradiation DNA radicals (DNA.) as a result of indirect da-
mage, mainly via hydroxyl radicals, can be restored (chemically re-
paired) to its original structure through reactions with reducing species
such as thiols. However, in the presence of oxygen then this may react
to produce a non-restorable organic peroxide (DNA-O2.) thus ‘fixing’
DNA into a permanent irreparable state (Hall and Giaccia, 2012; Grimes
and Partridge, 2015); this cannot occur in the absence of oxygen.
Oxygen effects in radiation is known as the Oxygen Enhancement Ratio
(OER) which is a measure of the increase in cell sensitivity to radiation
in the presence of oxygen. It is expressed as the ratio of radiation dose
required to produce a given effect in the absence of oxygen to the dose
required to produce the same effect in 1 atm of air (Hall and Giaccia,
2012). Tumours that are typically hypoxic (low oxygen level) conse-
quently show enhanced radio-resistance to photon radiation and
therefore require higher dosage of radiation to inactivate them. Reox-
ygenation has accounted for much of the success of fractionated
radiotherapy of hypoxic tumour cells; when a radiated tumour has
shrunk and re-oxygenation of tumour occurs (Withers, 1975) due to
reopening of temporarily occluded blood vessels; and also, resorption of
dead cells which lead to decreased distance from capillaries to tumour
cells (thus improving oxygen supply). The oxygen effect is greater for
low LET than high LET radiation.
Generally, it is accepted that longer duration courses of radiation
allow re-oxygenation in many human tumours; but for shorter treat-
ment courses the use of hypoxic cell sensitisation may be indicated,
especially as the clinical toxicities caused by these drugs can be related
to the duration of exposure.
3.1.5. Radiosensitivity
Different types of cell exhibit different intrinsic radio-sensitivity
which can be unique to the individual (Steel et al., 1989). Radiation
repair is the ability of the cells to repair sublethal damage (Elkind and
Sutton, 1959; Withers, 1975) and potential lethal damage (Phillips and
Tolmach, 1966). Different organs and different tissues have their own
intrinsic radiosensitive property. The law of Bergonie and Tribondeau
describes that tissue radiosensitivity depends on cells that are un-
differentiated, have a high division/proliferation capacity and divide
rapidly (Bergonie and Tribondeau, 1959) except lymphocytes; Casar-
ett's Classification according to tissue organization, cell kinetics and
microcirculation (Rubin and Casarett, 1968); and tissue architecture
according to Michalowski's Classification (Wheldon et al., 1982). That
implies that cells that divide and regenerate slowly are the most re-
sistant. Conversely, there are some glioblastoma cell lines that are low-
dose hypersensitive to radiation (Short et al., 1999).
In general, radiosensitivity is inversely related to repair capacity.
Thus, highly radiosensitive cells have low DNA repair capacity reflected
in their high α/β ratios which reflect the ratio of α, the coefficient of
cell kill per unit dose and β, the coefficient of cell kill per unit dose
squared. Radioresistant cells have low α/β ratios. Larger doses per
treatment are often suggested for low α/β systems and small doses per
fraction for high α/β systems (Jones and Dale, 2018). A summary of the
5 ‘Rs’ dose rate and LET effects on fractionated radiotherapy is provided
in Table 1.
3.2. Other phenomena of radiations as included in Table 2
3.2.1. Bystander effects
The “Bystander effects” refer to the induction of biological effects in
cells that are not directly traversed by radiation. The non-irradiated
cells that are located nearby the irradiated cells have also been ob-
served to respond to exposure, including the induction of DNA damage
and a reduction in clonogenic survival. This implies the target for ra-
diation biological effects is larger than the cell, observed in both high-
and low- LET radiations (Nagasawa and Little, 1999). The bystander
effect was demonstrated when Nagasawa and Little (1999) irradiated
less than 1% of cell nuclei with low doses of α particles, with an un-
expected high frequency of sister chromatid exchanges (Nagasawa and
Little, 1999). A wide range of bystander effects have been observed
including reduced clonogenic survival, increased sister chromatid ex-
changes, formation of micronuclei and apoptosis, genomic instability
and chromosomes abnormalities (Nagasawa and Little, 1999); apop-
tosis, cell death (Koturbash et al., 2008) and all these effects are similar
to the direct effect of radiation. Azzam et al. (1998) demonstrated that
the changes occur via cellular communication (Azzam et al., 1998;
Zhou et al., 2005), when irradiated cells send damage signals through
gap junctions to the neighbouring non-targeted cells and act as though
they have been hit by radiation (Azzam et al., 1998; Mothersill and
Seymour, 2001; Seymour and Mothersill, 2004; Prise and O'Sullivan,
2009). Cytokine (Kaminski et al., 2005), signalling pathways (Lehnert
and Goodwin, 1997; Narayanan et al., 1997; Iyer, 2000) and other
mechanisms such as inflammation, immune system, gene expression
and epigenetic modulators (Ilnytskyy and Kovalchuk, 2011), including
extracellular vesicles/exosomes (Jabbari et al., 2020; Le et al., 2017),
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also contribute to the bystander effects. These effects are inherently
linked to perturbation of intercellular signalling, which not only results
in effects observed in non-irradiated cells, but can also modify the re-
sponse of surrounding irradiated cells. Such effects have been demon-
strated across large dose gradients, similar to that produced by clinical
beams, where the experimental data show a modification of cell sur-
vival in the beam as a result of bystander signals effects.
This two-edged sword of bystander-effects, having anti-tumour ab-
scopal effects (see below) and abscopal effects in normal tissues, would
certainly seem to require attention in the radiotherapy treatment of
patients. As an example, normal oxygenated tissues will experience
greater cell death due to bystander-related mechanisms (Marín et al.,
2014); the bystander effects are one of the complications in radiation
exposure, potentially causing chromosomal damages that could lead to
near future carcinogenic risk (Dent et al., 2000). Conversely, bystander-
effects signalling (McMahon et al., 2015), autoimmune diseases or
chronic inflammation may also be beneficial to radiotherapy (Schaue,
2017). Thus, modification of bystander signalling could in principle be
used to modify radiation responses, but this does not appear to have
been realised so far. It is possible that the effect is an in vitro artefact,
similar to reduced PLD repair in vitro.
3.2.2. Low dose hypersensitivity
Low dose hypersensitivity (HRS) is the phenomenon in which irra-
diated mammalian cells are sensitive to doses below ~ 0.5 Gy but be-
come increased in radioresistance with higher doses, especially in re-
gard to radioresistant cells (Joiner et al., 1996). These HRS cells are
sensitive to low single doses as these low damage levels do not trigger
the cells to repair. With higher doses, HRS is followed by an increase in
radioresistance (Wouters et al., 1996). The mechanisms of HRS involve;
hypersensitivity of a subpopulation of the cells, impaired cell-cycle
regulation and a defective DNA repair system (Short et al., 2003, 2005;
Marples and Collis, 2008). Moreover, HRS could be a protective me-
chanism that has evolved to prevent cells from developing genomic
instability and mutations (Marples and Collis, 2008; Martin et al.,
2014).
3.2.3. Adaptive response
Adaptive response refers to cells that are pre-exposed to very low
doses of ionizing radiation and with subsequent exposure to high dose
will result in less genetic damage in the pre-exposed cells compared to
those that were not pre-exposed. This is attributed to the induction of
repair mechanisms triggered by the low dose exposure. This implies
that exposure of cells to a low dose of ionizing radiation can induce a
condition of enhanced radioresistance termed as “radio-adaptive re-
sponse” (Mothersill, 2006; Azzam and Little, 2004). Currently there is
very little information of the potential impact (if any) of this effect on
radiotherapy and how it could potentially be utilised to improve ther-
apeutic outcome.
3.2.4. Hormesis
Radiation hormesis is a biphasic dose response phenomenon in
which adaptive responses to low doses of ionizing radiation are bene-
ficial but are harmful at high doses (Luckey, 2006). The immune system
response to an ‘adapting’ or ‘pre-conditioning’ low-dose tends to elicit
stress responses and stimulate adaptation, a protective mechanism
(Feinendegen, 2005). This is contrary to the Linear-No-Threshold (LNT)
concept. Hormesis implies no exposure and very high-dose exposures
suppress the immune system as compared to low doses. The LNT model
of radiation risk is used for radiation protection purposes but has
overlooked the adaptive defences of the body that are triggered by low
dose radiation. This LNT-hypothesis has been described as inconsistent
by numerous experiments, as shown by both laboratory experiments
and in human exposures (Feinendegen et al., 2012; Oakley, 2015).
3.2.5. Abscopal effect
Abscopal (out of field) effects are related to bystander effects but
specifically refer to responses of other organs and tissues at a distance
from the target tissues (Mole, 1953). Murphy and Morton (1915) re-
moved tumours from mice, irradiated the mice, and returned the tu-
mours to the mice; comparison was made to the control group with the
tumours intact during irradiation (Murphy and Morton, 1915). The
results observed was that unirradiated tumours grafts shrank by 50%
and survived for approximately five weeks, while the control group
members died after one week, although these results could be due to
vascular disruption. Abscopal effects can also include induction of
genomic instability (Lorimore et al., 2003), cell death, and oncogenic
transformation in normal tissues. This out of field effect of localized
irradiation perturbing the organism as a whole, could be either bene-
ficial or detrimental (Siva et al., 2013). This two-edged sword, with
anti-tumour abscopal effects and abscopal effects in normal tissues also
require attention in the radiotherapy treatment for patients, in parti-
cular there being very little information on how these effects are
modulated by fractionations.
Table 2
Other less dominant phenomena of radiotherapy.
Phenomenon Features Authors
Bystander effect Neighbour non-irradiated cells exhibit radiation induced DNA damage and cellular consequences
similar to the irradiated cells, mediated by cytokine, cell-signalling through gap junctions and
inflammatory responses. Involves abscopal effect and secondary cancers. Most effective with
radiation doses of < 1 Gy but is also applicable to doses > 10 Gy.
(Prise and O'Sullivan, 2009; Hamada
et al., 2011)
Low dose hyper-radiosensitivity Usually for doses < 0.3 Gy, in rapidly proliferating cells with a high G2 cell cycle component. The
initial cell survival curve is linear and steep followed by shallower curve. Thought to be due to
induced repair (failure to arrest in G2). Cells become radioresistant at higher doses. Low doses
fractionated radiation therapy could be recommended.
(Joiner et al., 2001; Short et al., 2001;
Marples et al., 2004)
Adaptive response (AR) AR is an active process where low dose exposure induces ‘tolerance’ to subsequent high dose
exposure. The low-dose irradiated cells are stimulated to react and become more resistant to
subsequent irradiation (biological defence mechanism).
(Olivieri et al., 1984; Wolff, 1998;
Hamada et al., 2011)
Hormesis Low dose radiation for health. Beneficial at low doses but toxic at high doses. Low dose beneficial
effect stimulates the immune system and adaptive responses improve the functional ability of cells
and the organism. The physiologic response to ionizing radiation is directly proportional to the
logarithm of the dose.
(Luckey, 2006; Calabrese, 2014;
Calabrese and Mattsonm, 2017)
Abscopal effect Indirect anticancer effects of radiotherapy on tumours out of the radiation field. Local irradiation of
one tumour tissue involved in a response of another or similar tissue away from the irradiated site.
This systemic effect of the irradiated tumours is mediated by radiation-induced cytokines, relevant
factors causing a chronic inflammatory environment, leading to induction of genomic instability
and radiation susceptibility in both distant tumour (regression) and normal tissue (secondary
carcinogenesis).
(Mole, 1953; Siva et al., 2013)
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3.3. Current trend of radiotherapy – Particle radiotherapy
As presented above, where several of the 5 “Rs” constrain the ef-
fectiveness of photon radiotherapy for tumours, an alternative treat-
ment modality such as charged particle radiotherapy would seems to be
more effective, albeit, not for all types of tumours. Charged particle
therapies such as the use of proton and carbon ions have several
characteristics that are attractive to effective radiotherapy such as; high
LET resulting in higher relative biological effectiveness (RBE), reduced
repair capacity, lower OER and decreased cell-cycle dependence that
are less affected by the 5 “Rs” of radiobiology. Increasing LET results in
an increase in the frequency and complexity of these complex DSBs
which are more difficult to repair than simple DSBs, leading to an in-
crease in RBE. In addition to simple DSB, ionizing radiation can also
induce complex DSB, which are comprised of a DSB with additional
strand breaks and/or base damage within a few base pairs (Ward, 1985;
Goodhead, 1994, 1999). For high LET radiation, even in the absence of
oxygen, the complexity of the induced DNA damage is such that they
are very difficult to repair,altering the level of oxygen having little ef-
fect on the resulting biological response (Goodhead, 1994, 1999).
Likewise, the response is more or less independent of dose-rate, but
where lower LET values are found these mechanisms do modulate the
response. Therefore, as LET increases, RBE increases and OER de-
creases. Hence, proton radiotherapy OER will be higher than carbon ion
radiotherapy.
RBE compares the efficiency of different types of radiations to
produce a defined biological effectiveness referenced to photon radia-
tion. RBE is dependent on many factors such as LET, cell and tissue
type, biological endpoints, dose, dose rate or fractionation, ion species,
oxygenation status and many other influences (Hall and Giaccia, 2012;
Held et al., 2016). Clinically, RBE is used to calculate the Gy Equivalent
dose (GyE), the physical doses being multiplied by the RBE of the re-
lated ion used. The RBE for protons is low at ~1.2, similar to high
energy X-rays (Paganetti, 2002) and for carbon ions is ~3 for treatment
(Matsufuji et al., 2003; Tsujii et al., 2007). Although, proton and carbon
ion radiotherapy have superior dose distribution, the principal differ-
ence is LET. Protons have low LET and carbon ions have higher LET.
Moreover, the Bragg peak of particle also provides excellent preci-
sion at targeting of tumours by deposition maximum energy at the tu-
mour and minimising dose to OAR (Wilson, 1946). Larger tumours can
be covered by using particles of different energies to produce a spread-
out Bragg peak which can encompass the tumour accurately with pre-
cise imaging.
Owing to each of the heavy ion properties, there are always physical
limitations and uncertainties such as ‘delta rays’ (δ) arising from the
initial ionization events, multiple scattering from Coulomb interactions
with nuclei similar to the interactions with electrons, and range strag-
gling due to energy loss through interactions of ions with orbiting
electrons, losing a varying amount of energy with each interaction
(Chu, 2006; Lomax, 2009). These ion beam effects vary approximately
with the inverse square-root of the mass of the particle and could be
minimised by removing material from the beam line. Moreover, nuclear
fragmentations especially from heavier ions such as carbon ions also
degrade the accuracy of treatment planning and could undermine the
primary benefits of heavy ion radiotherapy as it contributes sig-
nificantly to the dose within the spread-out Bragg peak (Chu, 2006). All
these uncertainties and limitations, related to charged ion radiation
(delivery, treatment planning, physical and biological tissues vari-
abilities and doses) have been considered, studied and greatly over-
come in advance of the start of treatment and are continuously being
improved (Kanai et al., 1999; Matsufuji et al., 2003; Jäkel, 2009; Suit
et al., 2010).
4. Conclusion
Radiotherapy is in principle a local treatment modality that is
harnessed towards combating cancer. However as in present discussions
and with clinical evidence of long-range beneficial and other effects, the
issue of needing well-controlled radiation treatment is obvious. Cells,
tissues and organ response to radiation is multifactorial and complex in
nature. With increasing use of small-field (few mm and less), high-dose
per-fraction (dose escalation) treatments and high LET radiotherapy,
increasing consideration also needs to be made of the nature of the
human body response. A novel systemic mediator that could control
tumour expansion and also defend normal tissue would be most de-
sired. The ability to be able to predict the potential consequences of off-
target effects would enhance the radiation effectiveness and radiation
risk assessment. Moreover, out of field effects could also be factored
into treatment planning. Additionally, there are exciting prospects for
radiotherapy where new targets for adjuvant therapy are now possible.
It is also necessary to use mathematical optimisation techniques within
models of radiotherapy to combine the often-qualitative biological
knowledge with the quantitative effects of radiation provided that the
key operative parameters are known. Currently, the benefits for ex-
tending patients’ lives with quality of life would outweigh the un-
desirable body responses to radiation treatment.
Declaration of competing interest
The authors declare that they have no known competing financial
interests or personal relationships that could have appeared to influ-
ence the work reported in this paper.
Acknowledgement
We would like to thank Sunway University for the internal grant
(INT-2019 SHMS-CBP-03).
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.radphyschem.2020.108994.
References
Azzam, E.I., de Toledo, S.M., Gooding, T., Little, J.B., 1998. Intercellular communication
is involved in the Bystander regulation of gene expression in human cells exposed to
very low fluences of alpha particles. Radiat. Res. 150, 497–504.
Azzam, E.I., Little, J.B., 2004. The radiation-induced bystander effect: evidence and
significance. Hum. Exp. Toxicol. 23, 61–65.
Bergonie, J., Tribondeau, L., 1959. Interpretation of some results of radiotherapy and an
attempt at determining a logical technique of treatment/de quelques resultats de la
radiotherapie et Essai de Fixation d'une Technique Rationnelle. Radiat. Res. 11,
587–588.
Calabrese, E.J., 2014. Hormesis: a fundamental concept in biology. Microbial cell (Graz,
Austria) 1, 145–149.
Calabrese, E.J., Mattsonm, M.P., 2017. How does hormesis impact biology, toxicology,
and medicine? NPJ Aging Mech Dis 3, 13.
Chu, W.T., 2006. Overview of Light-Ion Beam Therapy. IAEA-TECDOC-1560.
Dale, R.G., 2019. Radiation repair models for clinical application. Br. J. Radiol. 92,
e20180070.
Dent, S.F., Klaassen, D., Pater, J.L., Zee, B., Whitehead, M., 2000. Second primary ma-
lignancies following the treatment of early stage ovarian cancer: update of a study by
the National Cancer Institute of Canada—clinical Trials Group (NCIC—CTG). Ann.
Oncol. 11, 65–68.
Elkind, M.M., Sutton, H., 1959. X-ray damage and recovery in mammalian cells in cul-
ture. Nature 184, 1293–1295.
Feinendegen, L.E., 2005. Evidence for beneficial low level radiation effects and radiation
hormesis. Br. J. Radiol. 78, 3–7.
Feinendegen, L., Pollycove, M., Neumann, R., 2012. Hormesis by Low Dose Radiation
Effects: Low-Dose Cancer Risk Modeling Must Recognize Up-Regulation of Protection.
Therapeutic Nuclear Medicine. Springer, pp. 789–805.
Fenech, M., Crott, J., Turner, J., Brown, S., 1999. Necrosis, apoptosis, cytostasis and DNA
damage in human lymphocytes measured simultaneously within the cytokinesis-
block micronucleus assay: description of the method and results for hydrogen per-
oxide. Mutagenesis 14, 605–612.
Fenech, M., Crott, J.W., 2002. Micronuclei, nucleoplasmic bridges and nuclear buds in-
duced in folic acid deficient human lymphocytes-evidence for breakage–fusion-
bridge cycles in the cytokinesis-block micronucleus assay. Mutat Res-Fund Mol M.
M.T. Chew, et al. Radiation Physics and Chemistry 178 (2021) 108994
8
504, 131–136.
Fenech, M., 2007. Cytokinesis-block micronucleus cytome assay. Nat. Protoc. 2,
1084–1104.
Figueroa-González, G., Pérez-Plasencia, C., 2017. Strategies for the evaluation of DNA
damage and repair mechanisms in cancer. Oncol Lett 13, 3982–3988.
Goodhead, D.T., 1994. Initial events in the cellular effects of ionizing radiations : clus-
tered damage in DNA. In: Radiat Res. Annual Meeting. Taylor & Francis, London, pp.
7–17 Guilford 1993-07-12.
Goodhead, D.T., 1999. Mechanisms for the biological effectiveness of high-LET radia-
tions. J. Radiat. Res. 40, S1–S13.
Gray, L.H., Conger, A.D., Ebert, M., Hornsey, S., Scott, O.C.A., 1953. The concentration of
oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br. J.
Radiol. 26, 638–648.
Grimes, D.R., Partridge, M., 2015. A mechanistic investigation of the oxygen fixation
hypothesis and oxygen enhancement ratio. Biomed Phys Eng Express 4, e045209.
Guo, G.Z., Sasai, K., Oya, N., Shibata, T., Shibuya, K., Hiraoka, M., 1999. A significant
correlation between clonogenic radiosensitivity and the simultaneous assessment of
micronucleus and apoptotic cell frequencies. Int. J. Radiat. Biol. 75, 857–864.
Hall, E.J., Giaccia, A.J., 2012. Radiobiology for the Radiologist, seventh ed. Lippincott
Williams & Wilkins.
Hall, E.J., Kraljevic, U., 1976. Repair of potentially lethal radiation damage: comparison
of neutron and X-ray RBE and Implications for radiation therapy. Radiology 121,
731–735.
Hamada, N., Maeda, M., Otsuka, K., Tomita, M., 2011. Signaling pathways underpinning
the manifestations of ionizing radiation-induced bystander effects. Curr. Mol.
Pharmacol. 4, 79–95.
Held, K.D., Kawamura, H., Kaminuma, T., Paz, A.E.S., Yoshida, Y., Liu, Q., Willers, H.,
Takahashi, A., 2016. Effects of charged particles on human tumor cells. Front Oncol
6, 23.
Hill, M., 2019. Radiation track structure: how the spatial distribution of energy deposition
drives biological response. Clin. Oncol. 32, 75–83.
Ilnytskyy, Y., Kovalchuk, O., 2011. Non-targeted radiation effects-An epigenetic con-
nection. Mutat. Res. 714, 113–125.
Iyer, R., 2000. Factors underlying the cell growth-related bystander responses to alpha
particles. Canc. Res. 60, 1290–1298.
Jabbari, N., Karimipour, M., Khaksar, M., Akbariazar, E., Heidarzadeh, M., Mojarad, B.,
Aftab, H., Rahbarghazi, R., Rezaie, J., 2020. Tumor-derived extracellular vesicles:
insights into bystander effects of exosomes after irradiation. Laser Med. Sci. 35,
531–545.
Jäkel, O., 2009. Medical physics aspects of particle therapy. Radiat. Protect. Dosim. 137,
156–166.
Joiner, M.C., Lambin, P., Malaise, E.P., Robson, T., Arrand, J.E., Skov, K.A., Marples, B.,
1996. Hypersensitivity to very-low single radiation doses: its relationship to the
adaptive response and induced radioresistance. Mutat Res-Fund Mol M. 358,
171–183.
Joiner, M.C., Marples, B., Lambin, P., Short, S.C., Turesson, I., 2001. Low-dose hy-
persensitivity: current status and possible mechanisms. Int. J. Radiat. Oncol. Biol.
Phys. 49, 379–389.
Joiner, M.C., Van der Kogel, A., 2016. Basic Clinical Radiobiology. CRC Press.
Jones, B., Dale, R.G., 2000. Radiobiological modeling and clinical trials. Int. J. Radiat.
Oncol. Biol. Phys. 48, 259–265.
Jones, B., Dale, R.G., 2018. The evolution of practical radiobiological modelling. Br. J.
Radiol. 92, e20180097.
Jones, B., Hopewell, J.W., 2018. Modelling the influence of treatment time on the bio-
logical effectiveness of single radiosurgery treatments: derivation of "protective" dose
modification factors. Br. J. Radiol. 92, e20180111.
Kaminski, J.M., Shinohara, E., Summers, J.B., Niermann, K.J., Morimoto, A., Brousal, J.,
2005. The controversial abscopal effect. Canc. Treat Rev. 31, 59–72.
Kanai, T., Endo, M., Minohara, S., Miyahara, N., Koyama-ito, H., Tomura, H., Matsufuji,
N., Futami, Y., Fukumura, A., Hiraoka, T., Furusawa, Y., Ando, K., Suzuki, M., Soga,
F., Kawachi, K., 1999. Biophysical characteristics of HIMAC clinical irradiation
system for heavy-ion radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 44, 201–210.
Koturbash, I., Loree, J., Kutanzi, K., Koganow, C., Pogribny, I., Kovalchuk, O., 2008. In
vivo bystander effect: cranial x-irradiation leads to elevated DNA damage, altered
cellular proliferation and apoptosis, and increased p53 levels in shielded spleen. Int.
J. Radiat. Oncol. Biol. Phys. 70, 554–562.
Le, M., Fernandez-Palomo, C., McNeill, F.E., Seymour, C.E., Rainbow, A.J., Mothersill,
C.E., 2017. Exosomes are released by bystander cells exposed to radiation-induced
biophoton signals: reconciling the mechanisms mediating the bystander effect. PloS
One 12, e0173685.
Lehnert, B.E., Goodwin, E.H., 1997. A new mechanism for DNA alterations induced by
alpha particles such as those emitted by radon and radon progeny. Environ. Health
Perspect. 105 (Suppl. 5), 1095–1101.
Little, J.B., 1968. Cellular effects of ionizing radiation. N. Engl. J. Med. 278, 369–376.
Lomax, A.J., 2009. Charged particle therapy: the physics of interaction. J. Canc. 15,
285–291.
Lorimore, S.A., Coates, P.J., Wright, E.G., 2003. Radiation-induced genomic instability
and bystander effects: inter-related nontargeted effects of exposure to ionizing ra-
diation. Oncogene 22, 7058–7069.
Luckey, T.D., 2006. Radiation Hormesis: the Good, the Bad, and the Ugly, vol. 4. Dose-
response : a publication of International Hormesis Society, pp. 169–190.
Mah, L.J., El-Osta, A., Karagiannis, T.C., 2010. γH2AX: a sensitive molecular marker of
DNA damage and repair. Leukemia 24, 679–686.
Marín, A., Martín, M., Liñán, O., Alvarenga, F., López, M., Fernández, L., Büchser, D.,
Cerezo, L., 2014. Bystander effects and radiotherapy. Rep. Practical Oncol. Radiother.
20, 12–21.
Marples, B., Wouters, B., Collis, S., Chalmers, A., Joiner, M.C., 2004. Low-dose hyper-
radiosensitivity: a consequence of ineffective cell cycle arrest of radiation-damaged
G2-phase cells. Radiat. Res. 161, 247–255.
Marples, B., Collis, S.J., 2008. Low-dose hyper-radiosensitivity: past, present, and future.
Int. J. Radiat. Oncol. Biol. Phys. 70, 1310–1318.
Martin, L.M., Marples, B., Lynch, T.H., Hollywood, D., Marignol, L., 2014. Exposure to
low dose ionising radiation: molecular and clinical consequences. Canc. Lett. 349,
98–106.
Matsufuji, N., Fukumura, A., Komori, M., Kanai, T., Kohno, T., 2003. Influence of frag-
ment reaction of relativistic heavy charged particles on heavy-ion radiotherapy. Phys.
Med. Biol. 48, 1605–1623.
Matsuya, Y., McMahon, S.J., Tsutsumi, K., Sasaki, K., Okuyama, G., Yoshii, Y., Mori, R.,
Oikawa, J., Prise, K.M., Date, H., 2018. Investigation of dose-rate effects and cell-
cycle distribution under protracted exposure to ionizing radiation for various dose-
rates. Sci. Rep. 8, 8287.
McMahon, S.J., McGarry, C.K., Butterworth, K.T., Jain, S., O'Sullivan, J.M., Hounsell,
A.R., Prise, K.M., 2015. Cellular signalling effects in high precision radiotherapy.
Phys. Med. Biol. 60, 4551–4564.
Mole, R.H., 1953. Whole body irradiation-radiobiology or medicine? Br. J. Radiol. 26,
234–241.
Mothersill, C., Seymour, C., 2001. Radiation-induced bystander effects: past history and
future direction. Radiat. Res. 155, 759–767.
Mothersill, C., 2006. Radiation-induced bystander effects and the DNA paradigm: an "Out
of field" perspective. Mutat. Res. 597, 5–10.
Murphy, J.B., Morton, J.J., 1915. The effect of Roentgen rays on the rate of growth of
spontaneous tumours in mice. J. Exp. Med. 22, 800–803.
Nagasawa, H., Little, J.B., 1999. Unexpected sensitivity to the induction of mutations by
very low doses of alpha-particle radiation:evidence for a bystander effect. Radiat.
Res. 152, 552–557.
Narayanan, P.K., Goodwin, E.H., Lehnert, B.E., 1997. α particles initiate biological pro-
duction of superoxide anions and hydrogen peroxide in human cells. Canc. Res. 57,
3963–3971.
Ng, W.L., Huang, Q., Liu, X.J., Zimmerman, M., Li, F., Li, C.Y., 2013. Molecular me-
chanisms involved in tumor repopulation after radiotherapy. Transl. Cancer Res. 2,
442–448.
Oakley, P., 2015. Is use of radiation hormesis the missing link to a better cancer treat-
ment? J. Canc. Ther. 6, 601–605.
Olivieri, G., Bodycote, J., Wolff, S., 1984. Adaptive response of human lymphocytes to
low concentrations of radioactive thymidine. Science 223, 594–597.
Paganetti, H., 2002. Relative biological effectiveness (RBE) values for proton beam
therapy. Int. J. Radiat. Oncol. Biol. Phys. 53, 407–421.
Phillips, R.A., Tolmach, L.J., 1966. Repair of potentially lethal damage in X-irradiated
HeLa cells. Radiat. Res. 29, 413–432.
Pouget, J.P., Georgakilas, A.G., Ravanat, J.L., 2018. Targeted and off-rarget (bystander
and abscopal) effects of radiation therapy: redox mechanisms and risk/benefit ana-
lysis. Antioxidants Redox Signal. 29, 1447–1487.
Prise, K.M., O'Sullivan, J.M., 2009. Radiation-induced bystander signalling in cancer
therapy. Nat. Rev. Canc. 9, 351–360.
Redon, C.E., Dickey, J.S., Bonner, W.M., Sedelnikova, O.A., 2009. γ-H2AX as a biomarker
of DNA damage induced by ionizing radiation in human peripheral blood lympho-
cytes and artificial skin. Adv. Space Res. 43, 1171–1178.
Rubin, P., Casarett, G.W., 1968. Clinical radiation pathology as applied to curative
radiotherapy. Cancer 22, 767–778.
Schaue, D., 2017. A century of radiation therapy and adaptive immunity. Front. Immunol.
8, e431.
Seymour, C.B., Mothersill, C., 2004. Radiation-induced bystander effects-implications for
cancer. Nat. Rev. Canc. 4, 158–164.
Short, S., Mayes, C., Woodcock, M., Joiner, M.C., 1999. Low-dose hypersensitivity in the
T98G glioblastoma cell line. Int. J. Radiat. Biol. 75, 847–855.
Short, S., Kelly, J., Mayes, C., Woodcock, M., Joiner, M., 2001. Low-dose hypersensitivity
after fractionated low-dose irradiation in vitro. Int. J. Radiat. Biol. 77, 655–664.
Short, S., Woodcock, M., Marples, B., Joiner, M., 2003. Effects of cell cycle phase on low-
dose hyper-radiosensitivity. Int. J. Radiat. Biol. 79, 99–105.
Short, S., Bourne, S., Martindale, C., Woodcock, M., Jackson, S.P., 2005. DNA damage
responses at low radiation doses. Radiat. Res. 164, 292–302.
Sinclair, W.K., 1968. Cyclic x-ray responses in mammalian cells in vitro. Radiat. Res. 33,
620–643.
Siva, S., Macmanus, M., Martin, R., Martin, O., 2013. Abscopal effects of radiation
therapy: a clinical review for the radiobiologist. Canc. Lett. 356, 82–90.
Steel, G.G., McMillan, T.J., Peacock, J.H., 1989. The 5Rs of radiobiology. Int. J. Radiat.
Biol. 56, 1045–1048.
Suit, H., DeLaney, T., Goldberg, S., Paganetti, H., Clasie, B., Gerweck, L., Niemierko, A.,
Hall, E., Flanz, J., Hallman, J., Trofimov, A., 2010. Proton vs carbon ion beams in the
definitive radiation treatment of cancer patients. Radiother. Oncol. 95, 3–22.
Thomas, P., Umegaki, K., Fenech, M., 2003. Nucleoplasmic bridges are a sensitive mea-
sure of chromosome rearrangement in the cytokinesis-block micronucleus assay.
Mutagenesis 18, 187–194.
Tobias, C.A., 1985. The future of heavy-ion science in biology and medicine. Radiat. Res.
103, 1–33.
Tsujii, H., Mizoe, J., Kamada, T., Baba, M., Tsuji, H., Kato, H., Kato, S., Yamada, S.,
Yasuda, S., Ohno, T., Yanagi, T., Imai, R., Kagei, K., Kato, H., Hara, R., Hasegawa, A.,
Nakajima, M., Sugane, N., Tamaki, N., Takagi, R., Kandatsu, S., Yoshikawa, K.,
Kishimoto, R., Miyamoto, T., 2007. Clinical results of carbon ion radiotherapy at
NIRS. J. Radiat. Res. 48 (Suppl. A), A1–A13.
Ward, J.F., 1985. Biochemistry of DNA lesions. Radiat. Res. 104, S103–S111.
Weichselbaum, R.R., Schmit, A., Little, J.B., 1982. Cellular repair factors influencing
M.T. Chew, et al. Radiation Physics and Chemistry 178 (2021) 108994
9
radiocurability of human malignant tumours. Br. J. Canc. 45, 10–16.
Weichselbaum, R.R., 1986. Radioresistant and repair proficient cells may determine
radiocurability in human tumors. Int. J. Radiat. Oncol. Biol. Phys. 12, 637–639.
Weichselbaum, R.R., Beckett, M., 1987. The maximum recovery potential of human
tumor cells may predict clinical outcome in radiotherapy. Int. J. Radiat. Oncol. Biol.
Phys. 13, 709–713.
Wheldon, T.E., Michalowski, A.S., Kirk, J., 1982. The effect of irradiation on function in
self-renewing normal tissues with differing proliferative organisation. Br. J. Radiol.
55, 759–766.
Wilson, R.R., 1946. Radiological use of fast protons. Radiology 47, 487–491.
Withers, H.R., 1975. The four R's of radiotherapy. Adv. Radiat. Biol. 5, 241–271.
Wolff, S., 1998. The adaptive response in radiobiology: evolving insights and implica-
tions. Environ. Health Perspect. 106 (Suppl. l), 277–283 1.
Wouters, B.G., Sy, A.M., Skarsgard, L.D., 1996. Low-dose hypersensitivity and increased
radioresistance in a panel of human tumor cell lines with different radiosensitivity.
Radiat. Res. 146, 399–413.
Xu, B., Kim, S.T., Lim, D.S., Kastan, M.B., 2002. Two molecularly distinct G(2)/M
checkpoints are induced by ionizing irradiation. Mol. Cell Biol. 22, 1049–1059.
Zhou, H.N., Ivanov, V.N., Gillespie, J., Geard, C.R., Amundson, S.A., Brenner, D.J., Yu,
Z.L., Lieberman, H.B., Hei, T.K., 2005. Mechanism of radiation-induced bystander
effect: role of the cyclooxygenase-2 signaling pathway. Proc. Natl. Acad. Sci. Unit.
States Am. 102, 14641.
M.T. Chew, et al. Radiation Physics and Chemistry 178 (2021) 108994
10
